Blog
RSS FeedPosted by Michael Wonder on 06 Apr 2026
Padcev, Tavneos clear key step toward reimbursement in Korea
3 April 2026 - Astellas Pharma Korea’s Padcev (enfortumab vedotin) for urothelial carcinoma and Meditip’s Tavneos (avacopan) for rare vasculitides ...
Posted by Michael Wonder on 03 Apr 2026
Changes to NICE’s cost effectiveness thresholds take effect
2 April 2026 - NICE has implemented new measures to evaluate the cost effectiveness of medicines, following a policy change that ...
Posted by Michael Wonder on 01 Apr 2026
Injection for more than a million people to help prevent heart attacks and strokes recommended
1 April 2026 - People who have had a heart attack, stroke, or serious circulation problem in their legs, and who ...
Posted by Michael Wonder on 31 Mar 2026
ICER publishes final evidence report on therapies for IgA nephropathy
31 March 2026 - Independent appraisal committee found a net health benefit for sibeprenlimab, atacicept, and Nefecon. ...
Posted by Michael Wonder on 30 Mar 2026
ICER to assess treatments for hypertension
30 March 2026 - Report will be subject of Midwest CEPAC meeting in October 2026; draft scoping document open to ...
Posted by Michael Wonder on 26 Mar 2026
UCB receives positive CHMP opinion for new Zilbrysq (zilucoplan) pre-filled pen in EU for adults living with generalised myasthenia gravis
26 March 2026 - UCB today announced that the CHMP of the EMA has issued a positive opinion recommending a ...
Posted by Michael Wonder on 25 Mar 2026
ICER launches program to accelerate the consideration of value into drug development programs
25 March 2026 - ICER will leverage its health technology assessment expertise to encourage better evidence development in clinical trial ...
Posted by Michael Wonder on 25 Mar 2026
Agenda for the July 2026 PBAC meeting (25 March 2026)
25 March 2026 - The agenda for the July 2026 PBAC meeting is now available. ...
Posted by Michael Wonder on 23 Mar 2026
EMA publishes agenda for 23-26 March 2026 CHMP meeting
23 March 2026 - The EMA has published a draft agenda for this week's CHMP meeting. ...
Posted by Michael Wonder on 20 Mar 2026
NHS spending watchdog to review evidence on Alzheimer’s treatments
20 March 2026 - England’s drugs costs watchdog is to look again at whether new treatments for Alzheimer’s disease should ...
Posted by Michael Wonder on 20 Mar 2026
Public summary documents (first time decisions not to recommend and deferrals) – November 2025 PBAC meeting
20 March 2026 - The Public Summary Documents (first time decisions not to recommend and deferrals) from the November 2025 PBAC ...
Posted by Michael Wonder on 12 Mar 2026
ICER releases draft evidence report on treatment for narcolepsy
12 March 2026 - Public comment period now open until 7 April 2026; requests to make oral comment during public ...
Posted by Michael Wonder on 12 Mar 2026
500,000 eligible to benefit from new non-hormonal treatment for hot flushes caused by menopause
11 March 2026 - A new treatment option for menopausal hot flushes and night sweats can be used in the NHS ...
Posted by Michael Wonder on 09 Mar 2026
ICER to assess treatment for Parkinson’s disease
9 March 2026 - Report will be subject of CTAF meeting in October 2026; draft scoping document open to public ...
Posted by Michael Wonder on 06 Mar 2026
Public summary documents – November 2025 PBAC meeting
6 March 2026 - The Public Summary Documents (positive recommendations and subsequent decisions not to recommend) from the November 2025 PBAC ...